FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s…
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from…
3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate…
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in…
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in…
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations,…
TORONTO, ON / ACCESS Newswire / October 17, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that…
Building a bridge between wellness and clinical care, Samsung and Xealth will create a health ecosystem that helps clinicians and…
MCLEAN, Va., Oct. 17, 2025 /PRNewswire/ -- ID.me and Flexpa today announced a partnership to make it easier and safer for…
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage…